Cargando…
Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization
The epidermal growth factor receptor (EGFR) is known to play a critical role in non-small cell lung cancer (NSCLC). Constitutively active EGFR mutations, including in-frame deletion in exon 19 and L858R point mutation in exon 21, contribute about 90% of all EGFR-activating mutations in NSCLC. Althou...
Autores principales: | Yeung, Yiu To, Yin, Shuying, Lu, Bingbing, Fan, Suyu, Yang, Ran, Bai, Ruihua, Zhang, Chengjuan, Bode, Ann M., Liu, Kangdong, Dong, Zigang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835564/ https://www.ncbi.nlm.nih.gov/pubmed/29398601 http://dx.doi.org/10.1016/j.ebiom.2018.01.017 |
Ejemplares similares
-
Losmapimod: A Novel Clinical Drug to Overcome Gefitinib-Resistance
por: Nishimura, Yukio
Publicado: (2018) -
244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells
por: Zhang, Yi, et al.
Publicado: (2015) -
Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis
por: Gipson, Debbie S., et al.
Publicado: (2020) -
Identification of a clinical compound losmapimod that blocks Lassa virus entry
por: Zhang, Xiaoyu, et al.
Publicado: (2019) -
Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod
por: Kragholm, Kristian, et al.
Publicado: (2015)